Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Aug:119:106902.
doi: 10.1016/j.leukres.2022.106902. Epub 2022 Jun 16.

Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study

Affiliations
Multicenter Study

Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study

Avraham Frisch et al. Leuk Res. 2022 Aug.

Abstract

Remission assessment in acute myeloid leukemia has evolved over the recent years with the advent of molecular and flow-based minimal residual disease determination. Nonetheless, early time point such as day 5 and day 14 (D14), still have prognostic and therapeutic implications. D14 refractory disease is regarded as a poor prognostic factor, however the therapeutic intervention is still under debate, with evidence suggesting a successful re-induction might offer similar long-term outcome as D14 aplasia. Others advocate the use of more intensive salvage protocols as a mean to overcome the negative prognostic effect. In the current study, we compare outcome of D14 refractory AML patients treated with either re-induction or salvage protocol. More importantly, we identify response characteristics that might suggest which patients will benefit from re-induction approach. Accurate identification of chemotherapy refractory patients might allow the early incorporation of non-chemotherapy based protocols in the future.

Keywords: Acute myeloid leukemia; D14.

PubMed Disclaimer

Publication types

LinkOut - more resources